Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Farmers Insurance
Federal Trade Commission
Cantor Fitzgerald
AstraZeneca
Teva
Chinese Patent Office
Daiichi Sankyo
McKinsey

Generated: July 20, 2018

DrugPatentWatch Database Preview

ENJUVIA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Enjuvia patents expire, and what generic alternatives are available?

Enjuvia is a drug marketed by Teva Branded Pharm and is included in one NDA. There are two patents protecting this drug.

This drug has seventeen patent family members in nine countries.

The generic ingredient in ENJUVIA is estrogens, conjugated synthetic b. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the estrogens, conjugated synthetic b profile page.
Summary for ENJUVIA
International Patents:17
US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 2
Formulation / Manufacturing:see details
DailyMed Link:ENJUVIA at DailyMed
Drug patent expirations by year for ENJUVIA
Generic Entry Opportunity Date for ENJUVIA
Generic Entry Date for ENJUVIA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage::
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ENJUVIA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded Pharm ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-001 Dec 20, 2004 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Teva Branded Pharm ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-002 Dec 20, 2004 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Teva Branded Pharm ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-004 May 10, 2004 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Teva Branded Pharm ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-001 Dec 20, 2004 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Premature patent expiration for: ENJUVIA

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
➤ Try a Free Trial ENJUVIA ➤ Try a Free Trial

Non-Orange Book US Patents for ENJUVIA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,749,989 Estrogenic compounds, methods of using and methods of administering the same ➤ Try a Free Trial
7,989,436 Estrogenic compounds and pharmaceutical formulations comprising the same ➤ Try a Free Trial
6,250,127 Heat-dissipating aluminum silicon carbide composite manufacturing method ➤ Try a Free Trial
8,227,454 Estrogenic compounds, pharmaceutical compositions and formulations comprising the same ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Accenture
Moodys
Fish and Richardson
Chubb
Merck
Citi
Teva
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.